活检与否: presumed骨样骨瘤经射频消融治疗的回顾性综述
单中心回顾性分析1990年1月至2023年8月共643例首次CT引导活检联合射频消融的疑似骨样骨瘤患者,活检病理证实骨样骨瘤445例(69.1%)、非诊断性184例(28.6%)、骨样骨瘤模拟病变15例(2.3%),模拟病变多为良性但含1例未具体分类癌;模拟病变男性占比46.7%,低于病理证实骨样骨瘤的74.1%(p=0.033);射频消融治疗失败率三组间无显著差异(p=0.24)。
要点
- 疑似骨样骨瘤中模拟病变仅占2.3%,多数为良性但可能为恶性。
- 模拟病变男性占比46.7%,低于病理证实骨样骨瘤的74.1%(p=0.033)。
- 射频消融治疗失败率三组间无显著差异(p=0.24)。
核心结论
- 骨样骨瘤模拟病变不常见、通常为良性但可能为恶性;模拟病变无男性优势;影像学表现提示骨样骨瘤的病变中,射频消融治疗失败率及病变部位在各病理组间无显著差异。
研究设计与样本
- 单中心回顾性研究,纳入1990年1月至2023年8月所有首次CT引导活检联合射频消融的疑似骨样骨瘤患者643例(中位年龄18岁,IQR 13-24岁,男性458例),根据病理结果分为活检证实骨样骨瘤、骨样骨瘤模拟病变和非诊断性病变。
关键影像表现/征象
- 活检证实骨样骨瘤445例(69.1%),非诊断性病变184例(28.6%),骨样骨瘤模拟病变15例(2.3%)。
- 骨样骨瘤模拟病变包括软骨母细胞瘤4例、软骨瘤3例、内生软骨瘤2例、非骨化性纤维瘤2例、Brodie脓肿1例、嗜酸性肉芽肿1例、纤维结构不良1例和未具体分类癌1例。
临床应用与阅片要点
- 作者指出,在射频消融时对疑似骨样骨瘤进行常规活检可识别骨样骨瘤模拟病变,这些病变罕见且可能为良性。
- 骨样骨瘤模拟病变男性占比46.7%,活检证实骨样骨瘤男性占比74.1%(p=0.033)。
- 治疗失败定义为需要后续手术或介入干预的残留或复发症状;活检证实骨样骨瘤组治疗失败24例(5.4%),非诊断性病变组8例(4.4%),骨样骨瘤模拟病变组2例(13.3%);总体活检结果比较p=0.24,组间两两比较无显著差异。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: First, to determine the frequency and spectrum of osteoid osteoma (OO)-mimicking lesions among presumed OO referred for radiofrequency ablation (RFA). Second, to compare patient sex and age, lesion location, and rates of primary treatment failure for OO based on histopathology results.
MATERIALS AND METHODS: A retrospective review was performed of all first-time combined CT-guided biopsy/RFA for presumed OO at a single academic center between January 1990 and August 2023. Lesions were characterized as "biopsy-confirmed OO", "OO-mimicking", or "non-diagnostic" based on pathology results. Treatment failure was defined as residual or recurrent symptoms requiring follow-up surgery or procedural intervention. Variables of interest were compared between pathology groups using Kruskal-Wallis, Fisher's exact, and Wilcoxon rank sum tests.
RESULTS: Of 643 included patients (median 18 years old, IQR: 13-24 years, 458 male), there were 445 (69.1%) biopsy-confirmed OO, 184 (28.6%) non-diagnostic lesions, and 15 (2.3%) OO-mimicking lesions. OO-mimicking lesions included chondroblastoma (n = 4), chondroma (n = 3), enchondroma (n = 2), non-ossifying fibroma (n = 2), Brodie's abscess (n = 1), eosinophilic granuloma (n = 1), fibrous dysplasia (n = 1), and unspecified carcinoma (n = 1). OO-mimicking lesions did not show male predominance (46.7% male) like biopsy-proven OO (74.1% male) (p = 0.033). Treatment failure occurred in 24 (5.4%) biopsy-confirmed OO, 8 (4.4%) non-diagnostic lesions, and 2 (13.3%) OO-mimicking lesions without a significant difference by overall biopsy result (p = 0.24) or pairwise group comparison.
CONCLUSION: OO-mimicking pathology is infrequent, typically benign, but potentially malignant. OO-mimicking lesions do not exhibit male predominance. There was no significant difference in RFA treatment failure or lesion location among lesions with imaging appearances suggestive of OO.
KEY POINTS: Question What is the frequency and spectrum of OO-mimicking lesions among presumed OO and what, if any, differences exist between these pathologies? Finding The study cohort included 69.1% OO, 28.6% lesions with non-diagnostic histopathology, and 2.3% OO-mimicking lesions. There was no difference in treatment failure or location among lesions. Clinical relevance Routine biopsy of presumed OO at the time of RFA identifies OO-mimicking lesions, which are rare and likely benign.
引用
- Tung EL, Vicentini JRT, Hung YP, et al. To biopsy or not to biopsy: a retrospective review of presumed osteoid osteomas treated by radiofrequency ablation. Eur Radiol. 2024. PMID: 39325182. doi:10.1007/s00330-024-11088-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。